Navigation Links
Drug to fight tumors also fights the flu and possibly other viruses
Date:2/28/2011

Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus. A new research report appearing in the March 2011 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that DMXAA could assist flu vaccines by causing the body to produce its own antiviral proteins, called interferons, which interfere with the virus's ability to spread. In addition, DMXAA may be a useful antiviral therapy to treat newly emerging strains of the flu for which a vaccine has not be developed.

"We are hopeful that DMXAA or similar agents can be used ultimately to blunt the impact of yearly influenza outbreaks, and perhaps, for other virus infections as well," said Stefanie Vogel, Ph.D., co-author of the study and Professor of Microbiology and Immunology at the University of Maryland, School of Medicine in Baltimore.

To make this discovery, Vogel and colleagues infected mice with a mouse-adapted influenza strain. When given DMXAA three hours before or after infection and then two days later, the infection was significantly less severe. In addition, they found that DMXAA protected cells from flu strains that are resistant to Tamiflu, one of the most advanced anti-flu drugs on the market. These discoveries suggest that DMXAA could potentially enhance the efficacy of current flu treatments and vaccines, and perhaps treat other viruses or bacteria. To be sure that DMXAA led to increased production of interferons, the researchers also tested it in mice that lacked a gene needed to produce interferon, and found that these mice received no benefit from DMXAA.

"H1N1 was a wake-up call that the flu remains a very serious disease, regardless of how "common" we may think it is," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "Every year this virus mutates, and history has shown us that new, very dangerous strains of this virus will continue to emerge. New drugs like this one that can combat this virusespecially drugs that are effective against newly emerging strainsmay prove to be lifesaving for millions of people around the world."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Chemical compounds in trees can fight deadly staph infections in humans
2. Good diets fight bad Alzheimers genes
3. Media advisory -- Partnering to Fight TB: The Role of a TB Vaccine PDP
4. Roses get celery gene to help fight disease
5. NRL scientists elevate warfighter readiness against invisible threats
6. Research suggests HIV causes rapid aging in key infection-fighting cells
7. Fighting the fight for healthy teeth
8. Scripps Research team creates new synthetic compound with HIV-fighting promise
9. Miscanthus has a fighting chance against weeds
10. The amount of adipose tissue should be taken into account in the fight against obesity
11. Researchers discover how natural drug fights inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: